Literature DB >> 22456432

Expression of hMLH1, hMSH2 and hMSH6 in small intestinal carcinomas.

Mi Jin Gu1, Young Kyung Bae, Aeri Kim, Seung-Mo Hong, Eunsil Yu, Jihun Kim, Kee-Taek Jang, Hee-Kyung Chang, Eun Sun Jung, Han-Ik Bae, Ghil Suk Yoon, Joon Mee Kim, Jung Yeon Kim, Gwang Il Kim, Young-Ha Oh, Kyu Yun Jang, Sun-Young Jun, Dae Woon Eom, Kye Won Kwon, Gyeong Hoon Kang, Jae Bok Park, Soon Won Hong, Soo Jin Jung, Ji Shin Lee.   

Abstract

BACKGROUND/AIMS: Although primary small intestinal carcinoma (SIC) is morphologically similar to colorectal carcinoma and shares many of the genetic changes of carcinogenesis, little is known about the role of defective mismatch repair (MMR) genes involved in the SIC. The aim of this study is to investigate the role of defective MMR genes and correlation between clinicopathological factors and loss of MMR protein in SIC.
METHODOLOGY: A total of 195 SIC cases were collected from 20 institutions in Korea and tissue microarrays (TMA) were made. The loss of expression of hMLH1, hMSH2 and hMSH6 was examined by immunohistochemistry (IHC).
RESULTS: The loss of expression of hMLH1, hMSH2 and hMSH6 was identified in 25/193 (13.0%), 25/193 (13%) and 29/195 (15%), respectively. The loss of hMSH2 expression was associated with retroperitoneal seeding. Patients with loss of hMSH6 expression had a tendency to invade deeply and a higher frequency of pancreas invasion. The loss of hMSH6 expression was associated less frequently with peritumoral adenoma. There was no survival difference by MMR protein expression status.
CONCLUSIONS: The loss of MMR protein was associated with some distinct clinicopathological features. MMR pathway seems to be major pathway in carcinogenesis of SICs. MMR defect seems to be related with sporadic-microsatellite instability (MSI).

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22456432     DOI: 10.5754/hge11601

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  7 in total

Review 1.  Clinical practice guidelines for duodenal cancer 2021.

Authors:  Kenji Nakagawa; Masayuki Sho; Mitsuhiro Fujishiro; Naomi Kakushima; Takahiro Horimatsu; Ken-Ichi Okada; Mikitaka Iguchi; Toshio Uraoka; Motohiko Kato; Yorimasa Yamamoto; Toru Aoyama; Takahiro Akahori; Hidetoshi Eguchi; Shingo Kanaji; Kengo Kanetaka; Shinji Kuroda; Yuichi Nagakawa; Souya Nunobe; Ryota Higuchi; Tsutomu Fujii; Hiroharu Yamashita; Suguru Yamada; Yukiya Narita; Yoshitaka Honma; Kei Muro; Tetsuo Ushiku; Yasuo Ejima; Hiroki Yamaue; Yasuhiro Kodera
Journal:  J Gastroenterol       Date:  2022-10-19       Impact factor: 6.772

2.  Prevalence and Molecular Characterization of Defective DNA Mismatch Repair in Small-bowel Carcinoma in a Japanese Hospital-based Population.

Authors:  Tetsuya Ito; Hideyuki Ishida; Okihide Suzuki; Noriyasu Chika; Kunihiko Amano; Keiichiro Ishibashi; Nao Kamae; Yuhki Tada; Kiwamu Akagi; Hidetaka Eguchi; Yasushi Okazaki
Journal:  J Anus Rectum Colon       Date:  2020-10-29

3.  LncRNA HOTAIR promotes human liver cancer stem cell malignant growth through downregulation of SETD2.

Authors:  Haiyan Li; Jiahui An; Mengying Wu; Qidi Zheng; Xin Gui; Tianming Li; Hu Pu; Dongdong Lu
Journal:  Oncotarget       Date:  2015-09-29

4.  Expression of human DNA mismatch-repair protein, hMSH2, in patients with oral lichen planus.

Authors:  Hao-Bo Li; Ying-Huai Zhang; Hui-Zhen Chen; Yong Chen
Journal:  Exp Ther Med       Date:  2014-11-06       Impact factor: 2.447

5.  Lynch syndrome-related small intestinal adenocarcinomas.

Authors:  Sun-Young Jun; Eui-Jin Lee; Mi-Ju Kim; Sung Min Chun; Young Kyung Bae; Soon Uk Hong; Jene Choi; Joon Mee Kim; Kee-Taek Jang; Jung Yeon Kim; Gwang Il Kim; Soo Jin Jung; Ghilsuk Yoon; Seung-Mo Hong
Journal:  Oncotarget       Date:  2017-03-28

6.  Clinical significance of chromodomain helicase/ATPase DNA binding protein 1-like and human mutL homolog 1 gene expression in cholangiocarcinoma.

Authors:  Jingwen Hua; Shiniao Li; Changwen Huang
Journal:  Oncol Lett       Date:  2018-06-28       Impact factor: 2.967

Review 7.  Current approaches to immunotherapy in noncolorectal gastrointestinal malignancies.

Authors:  Victor Hugo Fonseca de Jesus; Tiago Cordeiro Felismino; Milton José de Barros E Silva; Virgílio de Souza E Silva; Rachel P Riechelmann
Journal:  Clinics (Sao Paulo)       Date:  2018-10-18       Impact factor: 2.365

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.